• Vor Biopharma is like CRISPR Therapeutics, but focused on engineering stem cells to protect cancer patients from therapy.
• Vor Biopharma is like Kite Pharma for bone marrow transplants, making them safer and more effective for AML patients.
• Vor Biopharma is like Moderna, but developing an engineered cell platform to enable safer cancer treatments.

• VOR301 (trem-cel): An investigational genetically modified hematopoietic stem cell (HSC) therapy designed to be resistant to CD33-targeted treatments, enabling the safe deployment of such therapies against blood cancers like acute myeloid leukemia.
• VBP101 (trem-cel + Mylotarg): An investigational combination therapy that pairs VOR301 with gemtuzumab ozogamicin (Mylotarg), a CD33-targeted therapeutic, to specifically target and eliminate residual cancer cells in patients with acute myeloid leukemia.

Vor Biopharma (symbol: VOR) is a clinical-stage biotechnology company focused on developing novel cell and gene therapies for cancer, particularly acute myeloid leukemia (AML) and other hematological malignancies. As a company primarily engaged in research, development, and conducting clinical trials for its product candidates (such as VOR301, also known as trem-cel), it does not currently have commercialized products available for sale to end-users.

Therefore, Vor Biopharma does not have traditional "major customers" (either individuals or other companies purchasing its products or licensing its commercial technology) in the conventional sense. Its operations are funded primarily through equity financing and grants, rather than through revenue generated from product sales or significant commercial partnerships for its therapeutic candidates.

null

Jean-Paul Kress, Chief Executive Officer and Chairman

Dr. Kress brings decades of executive leadership experience in the pharmaceutical and biotech industries. He most recently served as Chief Executive Officer of MorphoSys, where he led the development, approval, and commercialization of Monjuvi® (tafasitamab), and advanced the company's pipeline through the landmark acquisition of Constellation Pharmaceuticals in 2021, which ultimately led to MorphoSys's subsequent acquisition by Novartis in 2024. Prior to that, he was CEO of Syntimmune, guiding its lead immunology program through to acquisition by Alexion Pharmaceuticals. He currently serves on the Board of Sanofi S.A.

Sandy Mahatme, Chief Financial Officer and Chief Business Officer

Mr. Mahatme brings more than 30 years of executive leadership experience in the biopharmaceutical industry. He co-founded National Resilience, Inc. in 2020, serving as President, Chief Operating Officer, and Chief Financial Officer, where he raised over $2.5 billion in equity and non-dilutive capital. Prior to Resilience, Mr. Mahatme served as Executive Vice President, Chief Financial Officer, and Chief Business Officer of Sarepta Therapeutics, leading capital formation efforts exceeding $3.5 billion and building the company's pipeline through strategic licenses, collaborations, and acquisitions. He also held senior roles at Celgene Corporation, Pfizer, Inc., and Ernst & Young, LLP. Mr. Mahatme currently serves on the boards of CRISPR Therapeutics and Idorsia Pharmaceuticals.

Dallan Murray, Chief Commercial Officer

Mr. Murray brings over 25 years of experience leading commercial strategy, global product launches, and customer-facing organizations in biotechnology and pharmaceutical companies. He joins Vor Bio from Sarepta Therapeutics, where he served as Executive Vice President, Chief Customer Officer, leading commercial and medical affairs organizations and the international business unit, and achieved approximately $1.8 billion in net product revenue in 2024. He has led or supported more than a dozen product launches, including INCIVEK at Vertex Pharmaceuticals, and global rollouts at Gilead Sciences, Biogen, and Johnson & Johnson.

Qing Zuraw, Chief Development Officer

Dr. Zuraw has over 25 years of experience leading complex global and U.S. clinical development programs across autoimmune, inflammatory, and immunologic diseases. Most recently, she served as Chief Development Officer and Head of Global Clinical Development for Autoimmune Diseases at RemeGen Co., Ltd., where she was a key leader in the successful development and execution of clinical trials for telitacicept across four indications, culminating in regulatory approvals in China for systemic lupus erythematosus, generalized myasthenia gravis, and rheumatoid arthritis. She also held senior leadership roles at Janssen Research & Development, Teva Pharmaceutical Industries Ltd., Akebia Therapeutics, Inc., Biogen Inc., and Covance, Inc.

Jeremy Sokolove, Chief Medical Officer

Dr. Sokolove brings over 18 years of experience leading clinical development and translational research in autoimmune and inflammatory diseases. Prior to joining Vor Bio, Dr. Sokolove was Chief Medical Officer In-Residence at Roivant Sciences, and previously served as Chief Medical Officer at Odyssey Therapeutics, guiding its transition to a clinical-stage organization. Earlier in his career, he held senior leadership positions at GlaxoSmithKline as Senior Vice President and Head of Clinical Pharmacology & Experimental Medicine, and at AbbVie as Head of Immunology Translational Science. He also served on the faculty at Stanford University Medical Center as a practicing rheumatologist and primary investigator.

The rapid advancement and adoption of highly effective, less intensive targeted therapies and immunotherapies for acute myeloid leukemia (AML) and other hematologic malignancies represent a clear emerging threat to Vor Biopharma. Vor's lead program, VOR301, is an engineered hematopoietic stem cell (eHSC) therapy designed to enable higher doses of chemotherapy by protecting healthy stem cells. If emerging less-intensive, targeted regimens (e.g., BCL-2 inhibitors like venetoclax in combination with hypomethylating agents or novel targeted agents) prove to be sufficiently effective and well-tolerated across broader patient populations, they could reduce the number of AML patients requiring intensive chemotherapy conditioning and subsequent stem cell transplantation. This potential shift in the standard of care away from high-dose chemotherapy could diminish the addressable market and clinical utility of Vor's eHSC platform, which is predicated on making intensive chemotherapy safer.

Vor Biopharma (VOR) is a clinical-stage biotechnology company primarily focused on developing treatments for blood cancers, with a pipeline that includes therapies for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS). The company has also licensed a product candidate for primary Sjögren's Disease. The addressable market sizes for their main products are outlined below:

• Acute Myeloid Leukemia (AML):
  • The global Acute Myeloid Leukemia market size was estimated at USD 1.83 billion in 2024 and is projected to reach USD 2.97 billion by 2029, with a compound annual growth rate (CAGR) of 10.15% during the forecast period.
  • Another estimate values the global AML market at USD 2.82 billion in 2025, with an expectation to reach USD 7.65 billion by 2035, growing at a CAGR of approximately 10.5% between 2026-2035.
  • A separate report projects the global market for AML to reach USD 4.6 billion by 2033, with an 8.5% CAGR over the forecast period.
  • In the United States, there were an estimated 20,050 new cases of AML in 2022. North America is anticipated to account for approximately 38.2% of the AML treatment market share in 2025.
• Myelodysplastic Syndromes (MDS):
  • The global market size for Myelodysplastic Syndromes (MDS) was valued at USD 1.8 billion in 2023 and is projected to grow to USD 3.7 billion by 2033, demonstrating a CAGR of 7.5%.
  • In 2023, the MDS market in the United States was estimated to be USD 0.8 billion.
• Primary Sjögren's Disease:
  • The global Sjögren's Syndrome market size was valued at USD 1.76 billion in 2022 and is projected to reach USD 3.65 billion by 2032, exhibiting a CAGR of 7.58% during the forecast period.
  • The Sjögren's Syndrome market in the United States was estimated at USD 0.82 billion in 2022.

Here are 3-5 expected drivers of future revenue growth for Vor Biopharma (VOR) over the next 2-3 years:

1. Commercialization of Telitacicept: Vor Biopharma is advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and toward commercialization to treat serious autoantibody-driven conditions globally. Success in ongoing clinical trials, particularly in China for indications like IgA Nephropathy and Generalized Myasthenia Gravis, and subsequent regulatory approvals, could lead to product sales revenue in the coming years.
2. Milestone Payments and Royalties from Licensing Agreements: A significant driver of future revenue is the strategic licensing agreement with RemeGen. This deal grants Vor Biopharma ex-Greater China rights to develop and commercialize telitacicept, with potential milestone payments up to $4 billion plus royalties. Achieving specified development and commercialization milestones under this agreement would directly contribute to future revenue.
3. New Strategic Partnerships and Collaborations: As a clinical-stage biotechnology company, Vor Biopharma may pursue additional collaborations with other pharmaceutical companies or research institutions. Such partnerships could provide financial support through upfront payments, research funding, and further milestone and royalty agreements, accelerating the development and potential commercialization of its pipeline assets, including its eHSC therapies.

Share Issuance

• In November 2025, Vor Biopharma priced an underwritten public offering of 10,000,000 shares of common stock at $10.00 per share, expecting gross proceeds of $100 million. The company also granted underwriters an option to purchase up to an additional 1,500,000 shares, which could bring total net proceeds to approximately $107.8 million if fully exercised.
• In June 2025, Vor Bio entered a private placement in public equity financing (PIPE) for approximately $175 million in gross proceeds, issuing prefunded warrants to purchase 700,000,000 shares of common stock.
• In December 2024, Vor Bio secured a $55.6 million private placement, issuing approximately 55.9 million shares of common stock and warrants for about 69.8 million additional shares.

Inbound Investments

• A $175 million private placement in June 2025 was backed by a syndicate of investors including RA Capital Management, Mingxin Capital, Forbion, Venrock Healthcare Capital Partners, Caligan Partners, and NEXTBio.
• A $55.6 million private placement in December 2024 was led by new investor Reid Hoffman, with participation from existing stockholder RA Capital Management.
• Vor Biopharma has received strategic investments from Johnson & Johnson Innovation—JJDC, Inc. and Novartis Institutes for BioMedical Research.

Outbound Investments

• In June 2025, Vor Bio acquired global rights (excluding China, Hong Kong, Macau, and Taiwan) to telitacicept from RemeGen Co., Ltd. for an initial payment of $125 million, which included an upfront payment of $45 million and $80 million in warrants to purchase common stock.

Capital Expenditures

• Capital expenditures were consistently reported as $1 million annually from 2022 to 2025.
• Proceeds from the November 2025 public offering are intended to fund operating expenses and capital expenditure requirements into the second quarter of 2027.
• Capital expenditures are aimed at general corporate purposes, including expanding the pipeline and platform, and advancing research and development of additional eHSC and internal CAR-T programs.